CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
Sign Up to like & getrecommendations! Published in 2022 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2022.02.006
Abstract: BACKGROUND AIMS Chimeric antigen receptor (CAR) T-cell therapy can be associated with significant toxicities. CAR-engineered natural killer (NK) cells provide a safer alternative while maintaining anti-tumor effects. Activated NK (aNK) cells are a clinical-grade cellular… read more here.
Keywords: receptor; ccr7; tumor; cd19 hank ... See more keywords